BioSpace News Archive

Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 1, 2023, notifying the Company that it is not in compliance with the minimum Market Value of Publicly Held Shares.

Saluda Medical, Inc. announced the publication of new health economic data in The Clinical Journal of Pain that provides the strongest ever economic case for the use of Evoke® Closed-Loop SCS with physiologic SmartLoop™ technology over open-loop SCS therapy.

Avinger, Inc. announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III L.P. into shares of a new series of convertible preferred stock.

INVO Bioscience, Inc. announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock.

A coalition of 40 organizations representing the scientific, veterinary and conservation communities are partnering to advocate for the protection of long-tailed macaque monkeys

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will present at the SHARE Series event on Monday, August 14, 2023 at 8:30 AM Eastern time.

Histologics, LLC., a leader in the diagnostic field of tissue sampling, proudly welcomes Jannalee Johnson as their new Business Development Consultant for Gynecologic and Wound Care, effective Monday, July 24th, 2023.

McKesson Medical-Surgical, an affiliate of the McKesson Corporation, will participate as a silver sponsor of the National Association of Community Health Centers National Health Center Week 2023 Aug. 6-12.

Bionano Genomics, Inc. announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023.

Arexvy (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.